Clasp Therapeutics

A vial moves from freezer to clinic

Somewhere in a Phase 1 unit, a nurse hangs a bag containing a molecule that did not exist as a medicine three years ago. It is designed to do one thing: find a single mutant protein fragment sitting on the surface of a cancer cell, grab a passing T cell, and introduce the two. The healthy cell next door, carrying no such flag, is left alone.

That is the whole bet. Clasp Therapeutics is a clinical-stage immuno-oncology company built on the unfashionable idea that precision beats firepower. While much of the field chased ever-more-potent ways to switch the immune system on, Clasp went looking for a way to aim it. The company spun out of Johns Hopkins, launched publicly in March 2024 with a $150 million Series A, and dosed its first patient in April 2025. Today it is small - around 41 people - and unusually pedigreed for its size.

T cell engagers had a tissue problem

The T cell engager is a clever piece of biology - an antibody-like molecule with two ends, one that clamps a T cell and one that clamps a cancer cell, forcing an execution that would not otherwise happen. The first generation worked, sometimes spectacularly, in blood cancers. Then the field tried to point them at solid tumors and ran into a wall: the surface proteins they targeted also appeared on healthy tissue. Aim at the tumor, and you often hit the lung, the gut, the skin. Toxicity, not potency, became the ceiling.

The founders saw the flaw clearly because some of them had spent careers cataloguing exactly what makes a cancer cell different. The answer was not on the cell surface, where most drugs look. It was inside - in the mutated proteins that drive the disease, chopped into fragments and displayed on the cell's outer wall by HLA molecules. Those fragments are cancer's fingerprints. Healthy cells do not carry them.

Two Hopkins legends and a roomful of operators

If you wanted to design a company to chase mutant peptides, you would want the person who mapped cancer's genome and the person who helped invent modern immunotherapy in the same room. Clasp got both. Bert Vogelstein, among the most cited scientists alive for his work on the genetics of cancer, co-founded it alongside Drew Pardoll, a pioneer of immuno-oncology - joined by Hopkins colleagues Kenneth Kinzler, Shibin Zhou, Kellie Smith and Nick Papadopoulos.

Science founders are common. Science founders who attract a seasoned drug developer to actually run the thing are rarer. Robert Ross - who had previously led Surface Oncology through to its acquisition by Coherus - joined as CEO in late 2023, a co-founder with a clinic-shaped view of the world. The bet they all signed up for: that you could turn a driver mutation into a reliable, off-the-shelf target, and build an antibody-like drug to act on it.

Fig. 2 - A leadership bench where the founders publish and the operators ship. The trick of biotech is keeping both in the same building.

pHLAre: a platform with a pun for a name

The platform is called pHLAre - precision HLA redirecting engagers, and yes, a play on the HLA molecules that flare mutant peptides into view. Each molecule is modular and antibody-like: one arm reads a specific mutant peptide presented by a patient's HLA, the other recruits a T cell. Because the target is a tumor-specific fragment rather than a shared surface protein, the company describes the result as off-the-shelf medicines aimed with what it calls absolute specificity.

The early pipeline goes straight for cancer's most-wanted list. CLSP-1025 targets the p53 R175H mutation; CLSP-5282 targets KRasG12V - including, the company notes, tumors that have already shrugged off a KRas small-molecule inhibitor. These mutations are appealing precisely because they show up early in tumor formation and stay conserved through metastasis and resistance. A target that never moves is a target worth building a company around.

The investors who bought the thesis

Conviction in biotech is measured in dollars and in who signs the check. Clasp's $150 million Series A was led by Catalio Capital Management, Third Rock Ventures and Novo Holdings, with Vivo Capital, Cure Ventures, Blackbird BioVentures, Pictet Alternative Advisors, the American Cancer Society's BrightEdge and Alexandria Venture Investments alongside. Total funding sits around $222 million. The clinic, not the cap table, will deliver the real verdict - but the money bought Clasp the years it needs to get there.

Widening immunotherapy's reach

Clasp's stated mission is to master the discovery, development and delivery of off-the-shelf precision immunotherapies that expand immuno-oncology's reach to previously untreatable cancers. Strip the corporate cadence and it reads as a single ambition: take the cancers that have resisted everything, find the mutation driving them, and build a drug that can act on it without burning down the patient.

It is an unglamorous kind of optimism. There are no promises of cures here, only a sharper tool and a clear theory of why it should work. For informed skeptics, that restraint is the point - Clasp is asking to be judged on data, not adjectives.

Back to the vial

Return to that Phase 1 unit, and the bag on the pole. If Clasp is right, that molecule is the first of a class - a way to convert any well-characterized driver mutation into a target, and any target into an off-the-shelf drug. KRAS and p53 are merely the opening arguments. The platform's promise is that the next one, and the one after, follow the same blueprint.

If Clasp is wrong, it joins a long list of elegant theories that the human body declined to honor. That is the honest stakes of the thing. But the question it is asking is the right one, and the people asking it have earned the benefit of the doubt. The vial hangs. The T cells clasp. The rest is data.